Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.
ARTICLES BY TYLER MENICHIELLO
-
![Winning strategy efficiency innovation-+GettyImages-1359225856]( "Easing Autologous Cell Collection, Automating Manufacturing")
Easing Autologous Cell Collection, Automating Manufacturing1/22/2025To circumvent the challenges of leukapheresis, CellProthera developed a novel method for collecting therapeutic stem cells from whole blood. CSO Ibon Garitaonandia, Ph.D., discusses the company's mission to streamline manufacturing.
-
![biochemical laboratory, research institute-GettyImages-1485990190]( "Industry Leaders On Analytical Method Development")
Industry Leaders On Analytical Method Development1/7/2025Experts from Bristol Myers Squibb and Moffitt Cancer Center discuss best practices for analytical method development, as well as how to manage the successful transfer of these methods.
-
![Short_6]( "Optimism For Biopharma In 2025")
Optimism For Biopharma In 202512/27/2024In this closing segment from the executive roundtable discussion, our panelists express their confidence in the industry's mission and maintain a positive outlook for the years ahead.
-
![Short_5]( "How Biotechs Can Navigate Market Uncertainty In 2025")
How Biotechs Can Navigate Market Uncertainty In 202512/27/2024In this segment of the executive roundtable discussion, our panelists weigh in on how to prepare for what may be a challenging financial climate in 2025.
-
![Short_4]( "Political Influences And Regulatory Implications For Biotech In 2025")
Political Influences And Regulatory Implications For Biotech In 202512/27/2024In this segment of the executive roundtable discussion, our panelists discuss the changing political landscape and its potential effects from a regulatory and economic point of view.
-
![short3]( "2025 Predictions For AI Use In Biotech")
2025 Predictions For AI Use In Biotech12/26/2024In this segment of the executive roundtable discussion, our panelists discuss the growing prevalence of AI and its implications, both good and bad. They share their thoughts on smart adoption and the need for regulatory guidance moving forward.
-
![short_2]( "Cell Therapy Manufacturing Trends And Advancements Continuing In 2025")
Cell Therapy Manufacturing Trends And Advancements Continuing In 202512/26/2024In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.
-
![SplashScreen]( "Exciting Areas Of Innovation For Cell Therapies")
Exciting Areas Of Innovation For Cell Therapies12/23/2024In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.
-
![Improvement, Competition, Pursuit, Challenge-GettyImages-519915153]( "Leveraging Directed Evolution To Optimize AAV Vector Design")
Leveraging Directed Evolution To Optimize AAV Vector Design12/18/20244D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.
-
![GettyImages-1295693748-mRNA]( "Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases")
Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases11/26/2024EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.
